Completed PHASE3 INTERVENTIONAL 2-arm NCT01868009

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease

Sponsor: GlaxoSmithKline

Conditions Pulmonary Disease, Chronic Obstructive

Interventions DISKUS ELLIPTA

Updated 6 times since 2017 Last updated: Jan 16, 2014 Started: May 31, 2013 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01868009, this PHASE3 trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Charleston, United States , Charlotte, United States , Clearwater, United States , Easley, United States , Greenville, United States , Huntersville, United States , Jasper, United States , Lafayette, United States , Leesburg, United States , Medford, United States and 7 more locations